# Kind Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kind-pharmaceutical

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.kindpharmaceutical.com/
- Total disclosed funding: $85M
- Latest round: Series C (Nov 12, 2025)
- Investors on record: 13

## About

Established in 2014 and headquartered in Hangzhou, China, Kind Pharmaceutical LLC is a multinational pharmaceutical company engaged in the research and development of innovative therapeutics. The company operates a U.S. research facility located at the Pharmaceutical Research Center in San Francisco and a China site in the Community of Industries in Zhejiang Province. In November 2025, it closed a series C funding round from Grand Invest, Tppoly Capital, Xiamen C&D Emerging Industry Equity Investment, Tailong VC, ZJ Biomedicine and High-end Equipment Industry Fund and other investors.

The company's products include AND17, AND19, Antibody-drug conjugates (ADCs), and AND021. AND017 is a small molecular inhibitor of prolyl hydroxylase, mimics the natural physiological regulation under hypoxia condition to stabilize HIF and promote the production of red blood cells to treat anemia. AND019 is a novel third generation selective estrogen receptor degrader, which is a competitive antagonist of estrogen receptor (ER) by binding with ER to mediate its degradation. AND021 program is currently under clinical candidate nomination step. It will be developed for HIF-2-dependent renal cell carcinoma and other difficult-to-treat diseases.

The company primarily generates revenue through research collaborations, licensing agreements and payments related to its drug discovery and development programs.

Following the series C funding round, Kind Pharmaceutical LLC plans to advance its ongoing global clinical programs, expand its R&D capabilities and further develop its pipeline of small-molecule and ADC therapeutics to address anemia and oncology indications.

## Funding rounds

- Series C, Nov 12, 2025 — NLVC, Guangzhou Financial Innovation Investment Holdings, Gaorong Ventures, Efung Capital, Xiamen C&D Emerging Industry Equity Investment, Guangzhou Development District City Development Fund, Guangzhou Industry Investment Holding Group, Tppoly Capital, HangZhou Capital, Tailong VC, ZJ Biomedicine and High-end Equipment Industry Fund, Grand Invest
- Series B, Dec 27, 2021, $50M — NLVC, Decheng Capital, Gaorong Ventures, Efung Capital
- Series A, Oct 10, 2019, $35M — Decheng Capital

## Investors

- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A, Series B
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series B, Series C
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series B, Series C
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B, Series C
- Guangzhou Financial Innovation Investment Holdings (https://capitalatlas.ai/funds/guangzhou-financial-innovation-investment-holdings) — Series C
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series C
- Guangzhou Development District City Development Fund (https://capitalatlas.ai/funds/guangzhou-development-district-city-development-fund) — Series C
- Guangzhou Industry Investment Holding Group (https://capitalatlas.ai/funds/guangzhou-industry-investment-holding-group) — Series C
- Tppoly Capital (https://capitalatlas.ai/funds/tppoly-capital) — Series C
- HangZhou Capital (https://capitalatlas.ai/funds/hangzhou-capital) — Series C
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series C
- ZJ Biomedicine and High-end Equipment Industry Fund — Series C
- Grand Invest — Series C